


CLAIMS

1. A compound of the Formula (I) or a pharmaceutically-acceptable adduct thereof



(I)

wherein:

R¹ is hydrogen, C₁₋₃ alkyl or -CH₂OMe;

R² is pyridinyl, optionally substituted on 1 ring carbon atom by a substituent independently
 10 selected from the group consisting of C₁₋₃ alkyl, difluoromethyl and trifluoromethyl; or

R² is pyrimidinyl, optionally substituted on 1 ring carbon atom by a substituent
 independently selected from the group consisting of C₁₋₃ alkyl, difluoromethyl and
 trifluoromethyl; or

R² is phenyl optionally substituted on 1 or 2 ring carbon atoms by a substituent
 15 independently selected from the group consisting of halo, difluoromethyl, trifluoromethyl,
 methoxy and -OCHF₂; and

R³ is hydrogen, C₁₋₃ alkyl or chloro.

2. A compound of formula (I) or a pharmaceutically-acceptable adduct thereof, as
 20 claimed in claim 1, wherein:

R¹ is hydrogen, methyl or -CH₂OMe;

R² is pyridinyl, optionally substituted on 1 ring carbon atom by a substituent independently
 selected from the group consisting of methyl, difluoromethyl and trifluoromethyl; or

R² is pyrimidinyl, optionally substituted on 1 ring carbon atom by a substituent independently selected from the group consisting of methyl, difluoromethyl and trifluoromethyl; or

R² is phenyl optionally substituted on 1 or 2 ring carbon atoms by a substituent independently selected from the group consisting of fluoro, chloro, difluoromethyl, trifluoromethyl, methoxy and -OCHF₂; and

R³ is hydrogen, methyl or chloro.

3. A compound of formula (I) or a pharmaceutically-acceptable adduct thereof, as claimed in claim 1, wherein:

R¹ is hydrogen, methyl or -CH₂OMe;

R² is pyridinyl, optionally substituted on 1 ring carbon atom by a substituent independently selected from the group consisting of methyl, difluoromethyl and trifluoromethyl; or

R² is pyrimidinyl, optionally substituted on 1 ring carbon atom by a trifluoromethyl; or

R² is phenyl optionally substituted on 1 or 2 ring carbon atoms by a substituent independently selected from the group consisting of fluoro, chloro, difluoromethyl and methoxy; and

R³ is hydrogen, methyl or chloro.

4. A compound as claimed in claim 1, or a pharmaceutically-acceptable adduct thereof, wherein R² is 6-(difluoromethyl)pyridin-2-yl, 3-chlorophenyl, 3,4-difluorophenyl or 3,5-difluorophenyl.

5. A compound as claimed in claim 1, or a pharmaceutically-acceptable adduct thereof, wherein R² is 6-(difluoromethyl)pyridin-2-yl.

6. A compound as claimed in claim 1, or a pharmaceutically-acceptable adduct thereof, wherein R² is 3-chlorophenyl.

7. A compound as claimed in claim 1, or a pharmaceutically-acceptable adduct thereof, wherein R² is 3,4-difluorophenyl.

8. A compound as claimed in claim 1, or a pharmaceutically-acceptable adduct thereof, wherein R² is 3,5-difluorophenyl.

9. A compound as claimed in claim 1, or a pharmaceutically-acceptable adduct thereof, wherein said compound is;

(*S*)-7-(3-chlorobenzyl)-6-methyl-2-(2-((1-methyl-1*H*-pyrazol-5-yl)amino)pyrimidin-4-yl)-6,7-dihydroimidazo[1,2-*a*]pyrazin-8(*5H*)-one;

(*S*)-7-((6-(difluoromethyl)pyridin-2-yl)methyl)-6-methyl-2-(5-methyl-2-((1-methyl-1*H*-pyrazol-5-yl)amino)pyrimidin-4-yl)-6,7-dihydroimidazo[1,2-*a*]pyrazin-8(*5H*)-one;

(*R*)-7-(3,4-difluorobenzyl)-6-(methoxymethyl)-2-(5-methyl-2-((1-methyl-1*H*-pyrazol-5-yl)amino)pyrimidin-4-yl)-6,7-dihydroimidazo[1,2-*a*]pyrazin-8(*5H*)-one; or

(*S*)-7-(3,5-difluorobenzyl)-6-methyl-2-(5-methyl-2-((1-methyl-1*H*-pyrazol-5-yl)amino)pyrimidin-4-yl)-6,7-dihydroimidazo[1,2-*a*]pyrazin-8(*5H*)-one.

10. A compound as claimed in claim 1, or a pharmaceutically-acceptable adduct thereof, wherein said compound is

(*R*)-7-(3,4-Difluorobenzyl)-6-(methoxymethyl)-2-(5-methyl-2-((1-methyl-1*H*-pyrazol-5-yl)amino)pyrimidin-4-yl)-6,7-dihydroimidazo[1,2-*a*]pyrazin-8(*5H*)-one.

11. A pharmaceutically-acceptable adduct of a compound of formula (I) as claimed in claim 1, which is (*R*)-7-(3,4-Difluorobenzyl)-6-(methoxymethyl)-2-(5-methyl-2-((1-methyl-1*H*-pyrazol-5-yl)amino)pyrimidin-4-yl)-6,7-dihydroimidazo[1,2-*a*]pyrazin-8(*5H*)-one Ethanesulfonic acid adduct.

12. A crystalline form of (*R*)-7-(3,4-Difluorobenzyl)-6-(methoxymethyl)-2-(5-methyl-2-((1-methyl-1*H*-pyrazol-5-yl)amino)pyrimidin-4-yl)-6,7-dihydroimidazo[1,2-*a*]pyrazin-8(*5H*)-one Ethanesulfonic acid adduct as claimed in claim 11.

13. A pharmaceutically-acceptable adduct of a compound of formula (I) as claimed in claim 1, which is (*R*)-7-(3,4-Difluorobenzyl)-6-(methoxymethyl)-2-(5-methyl-2-((1-methyl-1*H*-pyrazol-5-yl)amino)pyrimidin-4-yl)-6,7-dihydroimidazo[1,2-*a*]pyrazin-8(5*H*)-one Adipic acid adduct.

14. A crystalline form of (*R*)-7-(3,4-Difluorobenzyl)-6-(methoxymethyl)-2-(5-methyl-2-((1-methyl-1*H*-pyrazol-5-yl)amino)pyrimidin-4-yl)-6,7-dihydroimidazo[1,2-*a*]pyrazin-8(5*H*)-one Adipic acid adduct as claimed in claim 13.

15. A compound as claimed in any of the preceding claims, or a pharmaceutically-acceptable adduct thereof, for use as a medicament.

16. A compound as claimed in any of claims 1 to 14, or a pharmaceutically-acceptable adduct thereof, for use in therapy.

17. A compound as claimed in any of claims 1 to 14, or a pharmaceutically-acceptable adduct thereof, for use in the prevention or treatment of cancer in a warm blooded animal such as man.

18. A compound of the Formula (I), or a pharmaceutically-acceptable adduct thereof, as claimed in any of claims 1 to 14 for use in the treatment of NSCLC, pancreatic or colo-rectal cancers.

19. Use of a compound as claimed in any of claims 1 to 14, or a pharmaceutically-acceptable adduct thereof, in the manufacture of a medicament for the prevention or treatment of cancer in a warm blooded animal such as man.

20. Use of compound of the Formula (I), or a pharmaceutically-acceptable adduct thereof, as claimed in any of claims 1 to 14 in the manufacture of a medicament for the treatment of NSCLC, pancreatic or colo-rectal cancers.


21. A pharmaceutical composition comprising a compound of Formula (I) or a pharmaceutically-acceptable adduct thereof, as claimed in claim 1, and a pharmaceutically-acceptable diluent or carrier.

22. A combination suitable for use in the treatment of cancer comprising a compound of Formula (I) or a pharmaceutically-acceptable adduct thereof, as claimed in claim 1, and another anti-tumour agent.

23. A combination as claimed in claim 22 comprising a compound of Formula (I) or a pharmaceutically-acceptable adduct thereof, as claimed in claim 1, and a MEK inhibitor.

24. A process for preparing a compound of formula (VI), said process comprising:

- 5 a) reaction of a compound of formula (VIII) with a compound of formula (XVI) in the presence of a suitable base in a suitable solvent, under conditions of ambient or elevated temperatures;



wherein R¹ and R³ are defined for compound of formula (I) hereinbefore;

10 L¹ is a leaving group or a pre-cursor to a leaving group;

P³ is a protecting group; and

R⁴ is an alkyl group; and

- b) optionally, an intermediate sulfamic acid is removed under conditions of aqueous acid in a suitable solvent; and

15 c) removal of the protecting group P³ in the presence of a suitable acid in a suitable solvent, under ambient temperatures.